The Role of Radioactive Iodine Treatment in the Management of Differentiated Thyroid Cancer - An Oncologic Surgical Perspective

Iain Nixon, Jatin P. Shah, Mark Zafereo, R S Simo, I D Hay, C Suarez, Peter Zbären , A Rinaldo, A Sanabria, C Silver, Antti Mäkitie, Vincent Vander Poorten, Luiz P Kowalski, Ashok R Shaha, Gregory W. Randolph, Alfio Ferlito

Research output: Contribution to journalArticlepeer-review

Abstract

With improved understanding of the biology of differentiated thyroid carcinomaits management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one size -fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects..
This review considers the evidence base for the benefits of using RAI in the primary and recurrent setting as well as the side-effects and risks from RAI treatment. By considering the pros and cons of adjuvant therapy we present an oncologic surgical perspective on selection of treatment for patients, both following pre-operative diagnostic biopsy and in the setting of a post-operative diagnosis of malignancy.
Original languageEnglish
JournalEJSO - European Journal of Surgical Oncology
Early online date9 Jan 2020
DOIs
Publication statusE-pub ahead of print - 9 Jan 2020

Fingerprint

Dive into the research topics of 'The Role of Radioactive Iodine Treatment in the Management of Differentiated Thyroid Cancer - An Oncologic Surgical Perspective'. Together they form a unique fingerprint.

Cite this